The Effect of Isoflurane or Sevoflurane on Kidney Function
This study has been terminated.
Information provided by:
First received: September 2, 2005
Last updated: NA
Last verified: August 2005
History: No changes posted
The purpose of this study is to determine if isoflurane and sevoflurane have similar effects on the kidneys of people with impaired kidneys when the drugs administered with low gas flow into anaesthetic machines.
Drug: sevoflurane or isoflurane
Endpoint Classification: Bio-equivalence Study
Intervention Model: Parallel Assignment
Masking: Single Blind
Primary Purpose: Treatment
||Post-Operative Creatinine Changes In Patients With Pre-Existing Renal Impairment After Low-Flow Isoflurane Or Sevoflurane: A Randomised Clinical Trial
Primary Outcome Measures:
- Change in creatinine in first three postoperative days
| Estimated Enrollment:
| Study Start Date:
| Estimated Study Completion Date:
|Ages Eligible for Study:
||18 Years and older
|Genders Eligible for Study:
|Accepts Healthy Volunteers:
Adult patients for elective surgery who will:
- Need to stay at least one night, and
- Need general anaesthesia, and
- Have a pre-operative serum creatinine concentration greater than 130 umol/l.
- The patient refuses.
- The patient is less than 18 years of age.
- The patient is on pre-operative dialysis
- The anaesthetist plans to use only regional or total intravenous anaesthesia.
- Specific types of surgery: craniotomy, carotid, and cardiac.
Please refer to this study by its ClinicalTrials.gov identifier: NCT00144118
|Department of Anaesthesia, Austin Health
|Melbourne, Victoria, Australia, 3084 |
||David A Story, MD
||Department of Anaesthesia, Austin Health
No publications provided
History of Changes
|Other Study ID Numbers:
|Study First Received:
||September 2, 2005
||September 2, 2005
||Australia: Department of Health and Ageing Therapeutic Goods Administration
Additional relevant MeSH terms:
ClinicalTrials.gov processed this record on April 17, 2014
Central Nervous System Depressants
Physiological Effects of Drugs
Central Nervous System Agents
Platelet Aggregation Inhibitors